Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansari, Jawaher, Hussain, Syed A, Ansari, Asif, Glaholm, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588609/
https://www.ncbi.nlm.nih.gov/pubmed/23467578
http://dx.doi.org/10.2147/BTT.S25862
Descripción
Sumario:A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.

Ejemplares similares